Expertise in
55
conditions

Dr. Lubomir Sokol

Hematology | Oncology
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Expertise in
55
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Lubomir Sokol is a Hematologist and an Oncologist practicing medicine in Tampa, Florida.

Dr. Sokol is highly rated in 55 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 177 peer reviewed articles and participating in 6 clinical trials. Dr. Sokol is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Hospital Affiliations

Tampa General Hospital

Languages Spoken

English
Czech
Russian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Enrollment Status: Terminated
Publish Date: February 05, 2026
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drug: Umbralisib
Study Phase: Phase 2
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: CC-486, Duvelisib
Study Phase: Phase 1
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 25, 2021
Intervention Type: Drug
Study Drug: BNZ132-1-40
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

177 Total Publications

Flow cytometric analysis of phenotypes and naïve/memory/effector T-cell subsets of T-cell large granular lymphocytic leukemia.
Flow cytometric analysis of phenotypes and naïve/memory/effector T-cell subsets of T-cell large granular lymphocytic leukemia.
Journal: Leukemia & lymphoma
Published: May 13, 2026
Similar Doctors
Expertise in
42
conditions
Dr. David A. Sallman
Hematology | Oncology
Expertise in
42
conditions
Dr. David A. Sallman
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-566-0117
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Sallman is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sallman is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sallman is currently accepting new patients.

Expertise in
42
conditions
Dr. Rami S. Komrokji
Hematology | Oncology
Expertise in
42
conditions
Dr. Rami S. Komrokji
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-566-0119
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rami Komrokji is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Komrokji is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Sideroblastic Anemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Komrokji is currently accepting new patients.

Expertise in
22
conditions
Dr. Javier A. Pinilla
Hematology | Oncology
Expertise in
22
conditions
Dr. Javier A. Pinilla
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-820-1890
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Javier Pinilla is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Pinilla is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration. Dr. Pinilla is currently accepting new patients.

Frequently Asked Questions about Dr. Lubomir Sokol

How do I make an appointment with Dr. Lubomir Sokol?

You can book an appointment with Dr. Lubomir Sokol by calling their office at 813-692-4147. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lubomir Sokol a top-rated expert for T-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lubomir Sokol is classified as an Elite expert for T-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lubomir Sokol specialize in?

While Dr. Lubomir Sokol is a Hematology, they have specific expertise in T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Lubomir Sokol participate in research or clinical trials?

Yes. Dr. Lubomir Sokol has published 177 articles and abstracts on conditions like T-Cell Lymphoma. You can view a list of Dr. Lubomir Sokol's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lubomir Sokol accept my insurance?

Dr. Lubomir Sokol accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 813-692-4147 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sokol's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 27 Distinguished Conditions
View All 21 Advanced Conditions
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile